Implementation Facilitation Period vs Pre-Implementation Period: Percentage of Patients With OUD Who Experienced Opioid-related or Other Drug Overdose During Implementation
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0433 | 0.0385 | 0.0486 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0353 | 0.0307 | 0.0406 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00794 | 0.000824 | 0.015 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.23 | 1.02 | 1.47 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.24 | 1.02 | 1.49 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Implementation Facilitation Period than on Pre-Implementation Period | 126 | 66.7 | 1,210 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Implementation Facilitation Period | Implementation Facilitation: The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.~The start date of the implementation facilitation period for each site was reported by the study PI. | 272 | 6,289 | OG000 | ClinicalTrials.gov |
| Group 2 | Pre-Implementation Period | Pre-implementation period defined as the 12 months prior to the implementation start date for each site. | 188 | 5,325 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Percentage of Patients With OUD Who Experienced Opioid-related or Other Drug Overdose During Implementation | ClinicalTrials.gov |
| Description | Data will be extracted from patients electronic health records. Patients experienced an overdose if we observe any recorded overdose events within the first 12 months of the phase. Overdoses are not exclusively opioid-related, and include both fatal and nonfatal events. Counts in the first 12 months of the implementation facilitation period are compared to counts in the 12-month pre-implementation period. | ClinicalTrials.gov |
| Time frame | This outcome is measured for first 12 months of the implementation phase and is compared to the 12-month pre-implementation period. | ClinicalTrials.gov |
| Population | We used the suicide navigator data from PERC to identify fatal and non-fatal overdose events. Cohort is defined as veterans who had a visit with an associated OUD diagnosis during the relevant phases. Patients must be observed in phase for at least 30 days. Overdose - Veterans experienced an overdose if we find any recorded overdose events within the first 12 months of the phase. Overdoses are not exclusively opioid-related, and include both fatal and non-fatal events. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Consortium to Disseminate and Understand Implementation of Opioid Use Disorder Treatment | ClinicalTrials.gov |
| NCT number | NCT04178551 | ClinicalTrials.gov |
| Phases | NA | ClinicalTrials.gov |
| Conditions | Opioid Medication Assisted Treatment | ClinicalTrials.gov |
| Interventions | Implementation Facilitation | ClinicalTrials.gov |
| Lead sponsor | VA Office of Research and Development | ClinicalTrials.gov |
| Results first posted | 2025-11-10 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT04178551?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.